Janssen, a J&J company, and Pharmacyclics, a AbbVie business, said April 6 that the FDA weighed in on the decision to remove indications for “the treatment of patients with mantle cell lymphoma who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.”
The drug remains approved for adults with chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenström’s macroglobulinemia, and patients 1 and older with chronic graft versus host disease after failure of one or more lines of systemic therapy, according to the FDA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
